Virpax Pharmaceuticals Raises $6 Million to Advance Non-Opioid Pain Management Solutions

Virpax Pharmaceuticals Secures Funding to Enhance Pain Management Solutions

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company focused on innovative drug delivery systems for pain management, recently concludes a public offering that successfully raises $6.0 million. The offering, which includes shares of the company’s common stock priced at $0.20 per share, also features pre-funded warrants. The funding is earmarked primarily for advancing clinical trials for Probudur, Virpax's promising product candidate, as well as supporting marketing initiatives and general corporate activities. The exclusive placement agent for the offering, Spartan Capital Securities, LLC, has facilitated this strategic financial move.

The proceeds from this public offering allow Virpax to prioritize the clinical development of Probudur, which represents a non-opioid and non-addictive approach to pain management. In an industry grappling with the opioid crisis, Virpax aims to provide innovative solutions that improve patient quality of life while minimizing the risks associated with traditional pain treatment methods. The company is steadfast in its mission to develop proprietary drug-releasing technologies that cater to patients suffering from both pain and central nervous system disorders.

Virpax Pharmaceuticals operates under a framework of transparency and compliance, having conducted the offering under a registration statement filed with the SEC. The effective date of this registration was January 27, 2025, ensuring that all regulatory requirements are met. By fostering open communication with the financial community and focusing on advancing its research pipeline, Virpax positions itself as a forward-thinking entity in the pharmaceutical landscape. The company's shares continue to be traded on the Nasdaq Capital Market under the symbol “VRPX,” reflecting its commitment to growth and innovation.

In addition to the successful public offering, Virpax emphasizes its dedication to developing non-addictive treatments, which is crucial in today’s healthcare environment. The pharmaceutical company encourages interested parties to visit its website for more information on its initiatives and ongoing projects.

As Virpax Pharmaceuticals progresses in its clinical endeavors, the recent funding marks a significant step towards fulfilling its vision of providing effective, safe, and innovative pain management solutions that ultimately enhance the lives of patients.